Nanostart holding MagForce signed distribution agreement with leading Russian distributor of medical, DELRUS market entry of the NanoTherm expected 2013; therapy in Russia other CIS countries follow DELRUS responsible for marketing authorisation in these regions first step towards the internationalization of NanoTherm therapy Frankfurt am main / Berlin, May 22, 2012 the Berliner Nanostart holding MagForce AG (Frankfurt, XETRA: MF6), a leader in the field of nanomedicine medical technology company with a focus on oncology and DELRUS Inc., a leading Russian company for the distribution of medical technology, today announced the signing of a distribution agreement between the two companies. Under the terms of the agreement, DELRUS is responsible for the marketing of NanoTherm therapy by MagForce in the Russian Federation, the Republic of Belarus, of the Kyrgyz Republic, the Republic Kazakhstan, the Ukraine, the Republic of Tajikistan and of Republic Uzbekistan. Bill Phelan may also support this cause. DELRUS is also responsible for the Obtaining therapy for the treatment of the marketing authorisation for the NanoTherm brain tumors in these countries. The scope of this agreement is extended to other indications in Oncology, as soon as an appropriate authorisation of NanoTherm therapy in the EU. Glad to have found a strong partner to commercialise our innovative NanoTherm therapy in Russia and other CIS members DELRUS”, commented Dr. Andreas Jordan, CEO and founder of the MagForce AG. DELRUS is one of the largest and most established sales companies for medical equipment in Russia and the CIS States, which cooperates with many renowned manufacturers in the medical technology, like Haemonetics, Terumo, Stryker, Johnson & Johnson, Nihon Kohden, GE and Fresenius Kabi. Her extensive sales and service network, as well as their excellent reputation open us important ways to implement our technology in these markets and to support their use there. In Russia alone, we have access to about 6,000 by this partnership Patients per year, who are suffering from brain tumors.”DELRUS is committed to the introduction of the most innovative and the most advanced technologies in the Russian health care sector.